4.6 Letter

Neutrophil extracellular trap formation is regulated by CXCR2 in COPD neutrophils

Journal

EUROPEAN RESPIRATORY JOURNAL
Volume 51, Issue 4, Pages -

Publisher

EUROPEAN RESPIRATORY SOC JOURNALS LTD
DOI: 10.1183/13993003.00970-2017

Keywords

-

Funding

  1. AstraZeneca
  2. Boehringer Ingelheim
  3. BerlinChemie
  4. Chiesi
  5. Novartis
  6. SanofiAventis
  7. Teva
  8. GlaxoSmithKline

Ask authors/readers for more resources

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Editorial Material Oncology

Editorial: Treatment for Non-Small Cell Lung Cancer in Distinct Patient Populations

Junji Uchino, Torsten Goldmann, Hideharu Kimura

FRONTIERS IN ONCOLOGY (2022)

Article Allergy

Longitudinal Impact of Sputum Inflammatory Phenotypes on Small Airway Dysfunction and Disease Outcomes in Asthma

Mustafa Abdo, Frauke Pedersen, Anne-Marie Kirsten, Vera Veith, Heike Biller, Frederik Trinkmann, Erika von Mutius, Matthias Kopp, Gesine Hansen, Klaus F. Rabe, Thomas Bahmer, Henrik Watz

Summary: This study investigated the impact of airway inflammatory phenotypes on small airway dysfunction (SAD) and asthma outcomes. The results showed that patients with eosinophilic and mixed granulocytic asthma had worse lung function, higher exacerbation rates, and poorer symptom control compared to patients with paucigranulocytic asthma. Persistent mixed granulocytic asthma was associated with the worst SAD measures. Changes in sputum eosinophil counts were found to be an independent predictor for the longitudinal change in lung function.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2022)

Article Critical Care Medicine

Predictors and associations of the persistent airflow limitation phenotype in asthma: a post-hoc analysis of the ATLANTIS study

Tessa M. Kole, Elise Vanden Berghe, Monica Kraft, Judith M. Vonk, Martijn C. Nawijn, Salman Siddiqui, Kai Sun, Leonardo M. Fabbri, Klaus F. Rabe, Kian Fan Chung, Gabriele Nicolini, Alberto Papi, Chris Brightling, Dave Singh, Thys van der Molen, Sven-Erik Dahlen, Alvar Agusti, Rosa Faner, Jadwiga A. Wedzicha, Gavin C. Donaldson, Ian M. Adcock, Lies Lahousse, Huib A. M. Kerstjens, Maarten van den Berge

Summary: This post-hoc analysis investigates the determinants, clinical implications, and outcome of persistent airflow limitation (PAL) in patients with asthma. The study reveals that PAL is not only present in severe asthma, but also in a considerable proportion of patients with milder disease. In patients with mild asthma, PAL is associated with eosinophilic inflammation and a higher risk of exacerbations, suggesting the need for increased treatment intensity.

LANCET RESPIRATORY MEDICINE (2023)

Article Respiratory System

What have we learned from the German COPD cohort COSYCONET and where do we go from here?

Kathrin Kahnert, Carolina Fischer, Peter Alter, Franziska Trudzinski, Tobias Welte, Juergen Behr, Felix Herth, Hans-Ulrich Kauczor, Robert Bals, Henrik Watz, Klaus Rabe, Sandra Soehler, Inge Kokot, Claus Vogelmeier, Rudolf Joerres

Summary: COSYCONET 1 is the only large German COPD cohort that can be compared internationally. From 2010 to December 2013, a total of 2741 patients diagnosed with COPD were recruited and subsequently followed up. Various clinical questions were addressed using this comprehensive dataset, covering medication prescription, comorbidity analysis, biomarker assessment, radiological aspects, and health economic aspects. More than 60 publications of COSYCONET data are currently available internationally. This overview summarizes the obtained results, focusing on the relationships between different clinical and functional aspects and their potential practical consequences. Additionally, information on the follow-up study COSYCONET 2 is provided.

PNEUMOLOGIE (2023)

Article Respiratory System

Long-term effect of dupilumab on prevention of lung function decline in patients with uncontrolled moderate-to-severe asthma: ATLAS trial design

Lucia De Prado Gomez, Ian Pavord, William Busse, Christopher E. Brightling, Michael E. Wechsler, Klaus F. Rabe, Mei Zhang, Jun Xing, Juby A. Jacob-Nara, Paul J. Rowe

Summary: The ATLAS trial aims to evaluate the role of Dupilumab in preventing or slowing loss of lung function in patients with uncontrolled moderate-to-severe asthma. The trial will last for 3 years and compare the effects of Dupilumab and standard-of-care therapy on lung function decline. Outcome measures include exhaled nitric oxide fraction, exacerbations, asthma control, quality of life, and the utility of exhaled nitric oxide as a biomarker of lung function decline.

ERJ OPEN RESEARCH (2023)

Article Allergy

Dupilumab improves long-term outcomes in patients with uncontrolled, moderate-to-severe GINA-based type 2 asthma, irrespective of allergic status

Klaus F. Rabe, Ian D. Pavord, William W. Busse, Geoffrey L. Chupp, Kenji Izuhara, Arman Altincatal, Rebecca Gall, Nami Pandit-Abid, Yamo Deniz, Paul J. Rowe, Juby A. Jacob-Nara, Amr Radwan

Summary: This study analyzed the efficacy of dupilumab in patients with or without evidence of allergic asthma and type 2 inflammation according to current GINA guidelines. The results showed that dupilumab reduced asthma exacerbation rates and improved lung function and asthma control, regardless of the presence of allergic asthma.

ALLERGY (2023)

Review Critical Care Medicine

Targeting Type 2 Inflammation and Epithelial Alarmins in Chronic Obstructive Pulmonary Disease A Biologics Outlook

Klaus F. Rabe, Stephen Rennard, Fernando J. Martinez, Bartolome R. Celli, Dave Singh, Alberto Papi, Mona Bafadhel, Jigna Heble, Amr Radwan, Xavier Soler, Juby A. Jacob Nara, Yamo Deniz, Paul J. Rowe

Summary: COPD is a complex inflammatory airway disease with different types of inflammation, requiring targeted therapies and biomarkers for better management. Current treatments have limitations and there is a need for new strategies to address specific pathophysiological issues.

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2023)

Article Allergy

Dupilumab Efficacy in Patients with Uncontrolled Moderate-to-Severe Type 2 Asthma Regardless of Perennial Aeroallergen Sensitization

Jonathan Corren, David J. Jackson, Thomas B. Casale, Larry Borish, Klaus F. Rabe, William W. Busse, Jorge F. Maspero, Daniel J. Jackson, Nadia Daizadeh, Arman Altincatal, Amr Radwan, Angela Khodzhayev, Michel Djandji, Juby A. Jacob-Nara, Paul J. Rowe, Yamo Deniz

Summary: In this study, Dupilumab demonstrated good efficacy by reducing asthma exacerbations and improving lung function in patients with uncontrolled, moderate-to-severe T2 asthma. Furthermore, Dupilumab showed similar effects in improving clinical outcomes and reducing biomarkers levels regardless of allergen sensitization status or number.

JOURNAL OF ASTHMA AND ALLERGY (2023)

Article Respiratory System

Standardized airway wall thickness Pi10 from routine CT scans of COPD patients as imaging biomarker for disease severity, lung function decline, and mortality

Kathrin Kahnert, Rudolf A. Joerres, Hans-Ulrich Kauczor, Peter Alter, Franziska C. Trudzinski, Felix Herth, Bertram Jobst, Oliver Weinheimer, Sebastian Nauck, Pontus Mertsch, Diego Kauffmann-Guerrero, Juergen Behr, Robert Bals, Henrik Watz, Klaus F. Rabe, Tobias Welte, Claus F. Vogelmeier, Juergen Biederer

Summary: This study aimed to evaluate the association of Pi10, a measure of standardized airway wall thickness on CT, with exacerbations, mortality, and response to triple therapy in patients with COPD. The results showed that Pi10 was associated with COPD severity, comorbidities, lung function, respiratory therapy, and mortality, and it had some predictive ability.

THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE (2023)

Article Respiratory System

Clinical factors linked to the type of respiratory medication in COPD: results from the COSYCONET cohort

Peter Alter, Kathrin Kahnert, Franziska C. Trudzinski, Robert Bals, Henrik Watz, Tim Speicher, Sandra Soehler, Tobias Welte, Klaus F. Rabe, Emiel F. M. Wouters, Claus F. Vogelmeier, Rudolf A. Joerres

Summary: This study analyzed factors associated with the use of COPD drugs in non-interventional circumstances using data from the COSYCONET cohort. The results showed that the use of respiratory medication was related to the severity of COPD and GOLD grades.

THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE (2023)

Meeting Abstract Respiratory System

Impact of COVID-19 related alterations in circulating respiratory viruses on children and adult patients with recurrent wheeze and asthma

A. Peck, N. Maison, A. Hose, J. Omony, B. Schaub, R. Grychtol, A. Dittrich, C. Nitsche, S. Foth, M. Weckmann, M. Abdo, T. Bahmer, K. F. Rabe, H. Renz, G. Hansen, M. Kopp, E. Von Mutius

EUROPEAN RESPIRATORY JOURNAL (2022)

Meeting Abstract Respiratory System

Nasal airway epithelium differentiates between asthma and healthy subjects and identifies clinically relevant asthma endotypes

T. Karp, A. Faiz, H. A. M. Kerstjens, I. M. Boudewijn, M. Kraft, J. M. Vonk, M. C. Nawijn, I. H. Heijink, L. M. Fabbri, K. F. Rabe, G. Nicolini, A. Papi, C. Brightling, D. Singh, T. Van der Molen, S. Siddiqui, S. Christenson, V Guryev, M. Van den Berge

EUROPEAN RESPIRATORY JOURNAL (2022)

Meeting Abstract Respiratory System

Health-related quality of life (HRQL) is associated with small airway dysfunction (SAD) in mild COPD and smokers at risk - cross-sectional baseline data from CAPTO-COPD

F. Trinkmann, A. Kirsten, M. Abdo, K. F. Rabe, F. J. Herth, H. Watz, M. Abdo

EUROPEAN RESPIRATORY JOURNAL (2022)

Article Respiratory System

Predictive modeling of COPD exacerbation rates using baseline risk factors

Dave Singh, John R. Hurst, Fernando J. Martinez, Klaus F. Rabe, Mona Bafadhel, Martin Jenkins, Domingo Salazar, Paul Dorinsky, Patrick Darken

Summary: This study developed models to predict the rate of moderate/severe exacerbations in COPD patients based on baseline risk factors. Factors such as prior exacerbations, eosinophil count, and use of inhaled corticosteroids were found to be significant predictors of exacerbation risk. The models showed good fit and improved prediction metrics compared to a simplified model. These models can be useful for evaluating treatment decisions in individual COPD patients.

THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE (2022)

Meeting Abstract Critical Care Medicine

Long-Term Efficacy of Dupilumab in Patients with Oral Corticosteroid-Dependent Asthma With and Without Comorbid Chronic Rhinosinusitis and/or Nasal Polyps

P. Berger, A. Menzies-Gow, A. Peters, P. Kuna, K. F. Rabe, A. Altincatal, B. Ortiz, M. Djandji, S. Siddiqui, Y. Deniz, J. Jacob-Nara, P. J. Rowe

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2022)

No Data Available